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Abstract
Introduction: Methotrexate (MTX) induces macrophage apoptosis in vitro, but there is not much evidence for
increased synovial macrophage apoptosis in MTX-treated patients. Macrophage apoptosis is reported, however,
during clinical response to anti-tumor necrosis factor-alpha (TNF-a) treatments. This implies that TNF-a promotes
macrophage survival and suggests that TNF-a may protect against MTX-induced apoptosis. We, therefore,
investigated this proposal and the macrophage signaling pathways underlying it.
Methods: Caspase-3 activity, annexin-V binding/7-aminoactinomycin D (7-AAD) exclusion and cell-cycle analysis
were used to measure steps in apoptosis of primary murine macrophages and cells of the RAW264.7 macrophage
cell line that had been exposed to clinically-relevant concentrations of MTX and TNF-a.
Results: MTX induces apoptosis in primary murine macrophages at concentrations as low as 100 nM in vitro.
TNF-a, which has a context-dependent ability to increase or to suppress apoptosis, efficiently suppresses
MTX-induced macrophage apoptosis. This depends on NF-B signaling, initiated through TNF Receptor Type 1
ligation. Macrophage colony stimulating factor, the primary macrophage survival and differentiation factor, does
not activate NF-B or protect macrophages from MTX-induced apoptosis. A weak NF-B activator, Receptor
Activator of NF-B Ligand (RANKL) is likewise ineffective. Blocking NF-B in TNF-a-exposed macrophages allowed
pro-apoptotic actions of TNF-a to dominate, even in the absence of MTX. MTX itself does not promote apoptosis
through interference with NF-B signaling.
Conclusions: These findings provide another mechanism by which TNF-a sustains macrophage numbers in
inflamed tissue and identify a further point of clinical complementarity between MTX and anti-TNF-a treatments
for rheumatoid arthritis.
Introduction
Synovial inflammatory macrophages have a central role
in maintaining disease activity in rheumatoid arthritis
(RA). Macrophage numbers in tissue are regulated by
recruitment, local proliferation, local cell death and emi-
gration to draining lymph nodes [1,2]. Synovial macro-
phage apoptosis has also been observed in synovium in
RA [3,4]. A suppressed rate of apoptosis would contri-
bute to maintaining inflammatory macrophage numbers,
and thus clinical activity, in macrophage-dependent con-
ditions. An enhanced rate of synovial macrophage
apoptosis is reported in RA patients responding to anti-
TNF-a treatments [4] as a delayed, rather than an early
phenomenon [5]. Macrophage apoptosis has also been
reported in patients with Crohn’s disease after anti-
TNF-a treatment [6]. These observations suggest that
TNF-a directly, or indirectly, sustains macrophage survi-
val in these conditions.
TNF-a activity supports recruitment of macrophages
into RA synovium [7], but is not known to enhance the
proliferation of macrophages or to prevent the emigra-
tion of macrophages through lymphatics [2]. TNF-a,
however, may deliver either apoptotic or survival signals,
depending on the cell context. TNF-a is a ligand for
two related receptors, TNF-R1 (p55) and TNF-R2 (p75).
Macrophages and their bone marrow and blood-borne
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to TNF-R1 leads to assembly of a Death-Inducing Sig-
naling Complex (DISC) and ultimately activation of
downstream effector caspases-3/6/7. Where this is the
dominant consequence of TNF-R1 ligation, apoptosis
follows. In other circumstances, TNF-R1 initiates survi-
val signaling [9] through activation of the NF-Bp a t h -
way. TNF-a ligation to TNF-R1 can thus bring
apoptosis or survival, depending on the relative activities
generated in the DISC-initiated and NF-B pathways
[10]. Macrophage survival is notably dependent on
NF-B signaling. The transcriptionally active RelA/NF-
B1 (p65/p50) complex appearsi nm a c r o p h a g en u c l e i
constitutively during late differentiation and is important
for continuing survival [10,11]. In vivo,t h e r ei s
enhanced nuclear expression of RelA/NF-B1 in synovial
macrophages in RA [12], consistent with a role for
NF-B activity in maintaining macrophage survival.
The observations of enhanced apoptosis during anti-
TNF-a treatment imply that TNF-a predominantly
antagonises apoptosis in RA and Crohn’s disease [4,6].
On the other hand, methotrexate (MTX), an anti-
rheumatic drug that has demonstrable pro-apoptotic
effects on monocyte/macrophage cells in vitro,d o e sn o t
appreciably alter the synovial membrane macrophage
apoptosis rate in RA patients [3,13]. This led us to ques-
tion whether the presence of TNF-a in synovium was
providing a survival signal to macrophages in MTX-
treated patients, thus antagonizing one potential thera-
peutic function of MTX. That would provide additional
explanation for the clinical complementarity of MTX
and anti-TNF-a treatments in RA [14]. In the study of
Catrina et al., which demonstrated synovial macrophage
apoptosis in response to anti-TNF-a therapy, the major-
ity of patients were co-treated with MTX [4].
MTX is a folate analogue with numerous effects on
inflammatory cell proliferation and survival, cytokine
expression, angiogenesis, cell adhesion and reactive oxy-
gen production [15]. The known direct targets of MTX
are dihydrofolate reductase, thymidylate synthase
and 5-aminoimidazole-4-carboxamide ribonucleotide
(AICAR) transformylase [15]. Consequences of inhibit-
ing these enzymes include reduced availability of purines
and pyrimidines for DNA and RNA synthesis and accu-
mulation of AICAR. AICAR, by inhibiting enzymatic
deamination of adenosine and adenosine monopho-
sphate, is proposed to increase availability of adenosine
extracellularly, for anti-inflammatory effect through ade-
nosine cell surface receptors [16]. These effects are gen-
erally believed to be mediated by long-lived
polyglutamate forms of MTX, which are generated in
many cell types, including normal myeloid precursor
cells and myelocytic cancer cells [17].
Materials and methods
Materials
The Recombinant Macrophage-Colony Stimulating Fac-
tor (M-CSF) was obtained from R&D Systems (Sydney,
NSW, Australia). Annexin V conjugated to phycoery-
thrin (Annexin V-PE) and 7-amino-actinomycin
(7-AAD) were from BD Biosciences (Sydney, NSW,
Australia). Parthenolide was purchased from Alexis Bio-
chemicals (Lausen, Switzerland). Rabbit anti-IBa
(C-21) polyclonal antibody, anti-NF-B p65, anti-NF-B
p50, anti-c-Rel and anti-RelB were obtained from Santa
Cruz Biotechnology, Santa Cruz, CA, USA. Mouse
anti-phospho-IBa (Ser32/36) (5A5) and horseradish
peroxidase-conjugated anti-rabbit were from Amersham
Biosciences (Sydney, NSW, Australia). Methotrexate was
provided by Mayne Pharma Pty Ltd. (Adelaide, South
Australia, Australia). Etanercept came from Wyeth Aus-
tralia Pty Ltd. (Sydney, NSW, Australia). Recombinant
GST-rRANKL was kindly provided by Ming-Hao Zheng
and Jiake Xu, Centre for Orthopaedic Research, Univer-
sity of Western Australia [18]. All other reagents were
sourced from Sigma-Aldrich (Sydney, NSW, Australia),
unless otherwise indicated.
Cell culture
RAW264.7 cells were obtained from the American Type
Culture Collection and maintained in Dulbecco’sm o d i -
fied Eagle’s medium (Life Technologies, Carlsbad,
California, USA) with 10% low endotoxin fetal calf
serum (CSL, Melbourne, Australia), penicillin and genta-
micin (DMEM-FCS). Bone marrow-derived monocytes/
macrophages (BMDM) were collected from the femora
and tibiae of eight-week old female C57BL or BALB/c
mice, as previously described [19], with the approval of
the Animal Ethics Committee of The University of Wes-
tern Australia. Cells were expanded in M-CSF (30 ng/
mL)-supplemented DMEM-FCS for seven days at 37°C/
5% CO2/95% air. The experiments reported here were
conducted with BMDM from C57BL mice, but results
were comparable using BALB/c mice.
MTT cytotoxicity assay
Viability was estimated using the 3-(4,5-dimethyl-2-thia-
zolyl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT) assay.
BMDM (3 × 10
4 cells/well) were seeded in 24-well
plates in M-CSF-supplemented DMEM-FCS. After
48 hr, cells were treated with TNF-a for 3 hr, followed
by MTX exposure for 24 hr. At the end of treatments,
50 μL of MTT (5 mg/mL) was added to each well, and
cells were incubated at 37°C for 2 hr. Formazan crystals
were then solubilised with 150 μL of 44% dimethyl for-
mamide/20% SDS at room temperature for at least
30 minutes on a rocking platform. A total of 100 μL
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reader (POLARstar OPTIMA,B M G ,G e r m a n y ) .T r i p l i -
cate assays were conducted for all conditions.
Caspase-3 protease activity
RAW264.7 cells and BMDM were cultured in six-well
plates at a density of 0.3 × 10
6 cells/well for 48 hr. After
treatments, trypsin-detached RAW264.7 cells and scraped
BMDM were lysed and assayed for caspase-3 activity as
described previously [20].
Flow cytometry analysis
Apoptotic cells were quantitated by staining with
annexin V-PE and 7-AAD, as specified by the manufac-
turer (BD Biosciences). Flow cytometry was performed
on populations of 5000-10,000 cells (Becton Dickinson
FACSCalibur, Sydney, NSW, Australia), with fluores-
cence of annexin V-PE and 7-AAD measured with a
585/42 nm bandpass filter (FL2 channel) and a 670 nm
longpass filter (FL3 channel), respectively. Data are
expressed as percentages of apoptotic cells, as defined
by annexin-V-PE positivity and 7-AAD negativity.
Cell cycle analysis
RAW264.7 cells and BMDM (0.25 × 10
6/well of a 12-well
plate) were collected and washed in cold Dulbecco’s
Phosphate Buffered Saline (DPBS) before being fixed
with 70% ethanol at -20°C. After 24 hr, cells were cen-
trifuged at 500 × g for 10 minutes at 4°C and resus-
pended in 500 μL of staining buffer (50 μg/mL
propidium iodide and 25 μg/mL RNase in 0.1% Triton
X-100). After incubating at 37°C for 30 minutes, cells
were analysed on a FACSCalibur flow cytometer (Becton
Dickinson) using a doublet discrimination protocol.
Western blot analysis
RAW264.7 cells and BMDM (1 × 10
6 per treatment) were
washed with ice-cold DPBS and lysed in RIPA buffer
(50 mM Tris, pH 7.5, containing 150 mM NaCl, 1% IGE-
PAL, 1% sodium deoxycholate, 0.1% SDS and 10 mM
EDTA) supplemented with 1X complete protease inhibi-
tors (Roche Applied Science, Sydney, NSW, Australia).
At o t a lo f2 0μg of total protein was separated by SDS-
PAGE and transferred to Hybond-P PVDF membranes
(Amersham Biosciences). Membranes were blocked in
1% BSA/5% non-fat milk in TTBS (10 mM Tris, pH 7.6,
150 mM NaCl, 0.1% Tween 20) for one hour at room
temperature, before being probed with specific antibodies
to phospho-IBa (1:1000 dilution), IBa (1:2,000) or
b-actin (1:8,000). Horseradish peroxidase-conjugated anti-
rabbit and anti-mouse were used at 1:8,000 and 1:20,000
dilutions, respectively. All antibodies were prepared in Sig-
nalBoost Immunoreaction Enhancer (Calbiochem, Darm-
stadt, Germany) and applied for one hour at room
temperature. Blots were revealed with enhanced chemilu-
minescence (ECL) reagents (Amersham Biosciences).
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed on nuclear extracts from RAW264.7
cells (8 × 10
6 per treatment) that were treated with 10 ng/
mL TNF-a for up to one hour, according to previously
described protocols [21]. A double-stranded NF-B
consensus oligonucleotide probe 5’-GGGCATGGGAA
TTTCCAACTC-3’ (0.25 pmol) with 5’-G overhangs was
filled in with labeled (a-
32P)dCTP (Amersham Pharmacia
Biotech, Buckinghamshire, England) using the Klenow
fragment of E. coli DNA polymerase I (Promega, Madison,
Wisconsin, USA). This DNA probe was incubated with
3 μg of nuclear proteins for 10 minutes at room tempera-
ture. Where indicated, antibodies (1 μg) to specific NF-B
factors or unlabelled oligonucleotide probes at 100-fold
molar excess were also included for supershift EMSA and
competition experiments, respectively. Samples were loaded
onto a 4% polyacrylamide gel, containing 0.25X Tris-
Borate-EDTA buffer, which had been pre-run for two hours
in the same buffer. After separation, gels were exposed to
Cronex X-ray film, using a single intensifying screen.
Transient transfection of RAW264.7 cells and BMDM with
an NF-B reporter plasmid
RAW264.7 cells (1 × 10
7) were transiently transfected
with 0.5 μg of pNFB-TA-Luc (Mercury™ Pathway pro-
filing system, BD Biosciences) by the DEAE-dextran
procedure, as previously described [21]. Transfected
cells were resuspended in DMEM-FCS and distributed
into a 24-well culture plate at a density of 3.3 × 10
5
cells/well. Cells were rested for 48 hr before experimen-
tation. Firefly luciferase expression in transfected
RAW264.7 cells was measured using the Promega Luci-
ferase Assay System, according to the manufacturer’s
instructions. Promoter activity was quantified by mea-
suring light production in a multifunctional microplate
reader (POLARstar OPTIMA, BMG, Germany), and
presented as relative light units (RLU).
BMDM were transfected with Lipofectamine™ and
Plus reagents (Invitrogen) according to manufacturer’s
instructions. Briefly, for each 24-well, 1 μgp N F - B-TA-
Luc was combined with 0.5 μL Plus reagent and 2 μL
Lipofectamine™ in antibiotic-free medium. A total of
1.5 × 10
5 cells/well was added to the transfection mix-
ture and plated in M-CSF-containing DMEM-FCS. After
four to six hours of incubation at 37°C, wells were
replaced with fresh growth medium. Luciferase expres-
sion was measured at least 48 hr after transfection.
Statistical analysis
Statistical significance (P < 0.05) between groups of experi-
mental data was assessed using paired Student’s t-tests.
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TNF-a protects primary macrophages and a macrophage
cell line from MTX-induced apoptosis
M-CSF is the primary growth, differentiation and survi-
val factor for macrophages under physiological condi-
tions. Serum concentrations of M-CSF are elevated to
approximately 0.6 ng/ml in patients with RA [22], but
concentrations in synovium are unknown. In vitro,a
concentration of 30 ng/ml was optimal for sustaining
the growth and survival of bone marrow-derived macro-
phages (BMDM) of C57BL/6 mice (results not shown).
In the presence of 30 ng/mL M-CSF, exposure to
10 μMM T Xf o r2 4h rc a u s e da na p p r o x i m a t e l y2 5 %
loss of cell numbers in BMDM cultures (Figure 1A).
This was related to increased apoptosis, as estimated by
caspase-3 activity (Figure 1B), annexin-V binding (early
apoptosis; Figure 1B) and increased sub-G0 (apoptotic)
fraction on flow cytometric cell cycle analysis (Table 1).
The proportion of cells in S-phase also increased with
MTX, consistent with its known action on completing
DNA synthesis [23] (Table 1).
Caspase-3 activation was evident at concentrations as
low as 0.1 μM MTX in BMDM, with activity increasing
dose-dependently up to 10 μM( F i g u r e1 C ) .M T X ,
therefore, induces macrophage apoptosis at levels
usually attained in treated human RA patients [24]. This
was replicated in the murine RAW264.7 macrophage cell
line (Figure 1E). RAW264.7 macrophages do not require
exogenous M-CSF to proliferate, having gained growth
signaling through introduction of the Abelson leukaemia
virus [25]. They have been previously found to model
primary macrophage apoptosis response [26]. A concen-
tration of 10 μM MTX was used in subsequent
experiments.
TNF-a could also maintain the viability of macro-
phages exposed to 10 μMM T X .T N F - a,w h e ni n t r o -
duced three hours before MTX, completely prevented
the loss of cell numbers in primary BMDM cultures
exposed to MTX (Figure 1A). TNF-a also almost com-
pletely inhibited MTX-induced caspase-3 activation
(Figure 1B) and annexin-V binding (Figure 1B) and sig-
nificantly suppressed the sub-G0 (apoptotic) fraction on
flow cytometric cell cycle analysis of MTX-exposed
BMDM (Table 1). TNF-a did not reverse the MTX-
induced increase in cells in S-phase. TNF-a, therefore,
protected from MTX-induced cell loss by countering
apoptosis, not through any action on cell proliferation.
TNF-a also reduced the sub-G0 population of M-CSF-
deprived BMDM, without restoring S phase progression
(Table 1). It is notable that TNF-a was protective even
in the presence of M-CSF concentrations that are opti-
mal for apoptosis prevention, suggesting distinct path-
ways for apoptosis protection. Further increases in
M-CSF concentration in culture, up to 120 ng/mL,
failed to substitute for the anti-apoptotic action of TNF-
a (results not shown). This suggested an action that was
independent of M-CSF intracellular signaling and
removed the possibility that TNF-a was acting through
autocrine induction of M-CSF secretion. At least three
hours of pre-exposure to TNF-a was required for opti-
mal protection from MTX-induced apoptosis (results
not shown).
TNF-a provided comparable protection from MTX-
induced apoptosis in the RAW264.7 macrophage cell line.
TNF-a exposure significantly (P < 0.05) suppressed
spontaneous apoptosis of RAW264.7 cells as measured by
caspase-3 activity and annexin-V binding (Figure 1D).
RAW264.7 cells shared the susceptibility of primary
macrophages to MTX, demonstrating enhanced caspase-
3 activity and annexin-V binding after six hours of
exposure (Figure 1D). This increase was markedly sup-
pressed when TNF-a was added three hours before
MTX (Figure 1D). Thus, the anti-apoptotic effect of
TNF-a is replicated in RAW264.7 cells, allowing use of
this cell line for studying the phenomenon.
TNF-a protection from apoptosis is mediated through
TNF-R1 (p55), not TNF-R2 (p75) receptor activation
Monocytes/macrophages express both TNF-R1 and
TNF-R2 [8]. To determine the receptor subtype(s) that
mediated the survival effect of TNF-a, we exploited the
species specificity of TNF-a action. Murine TNF-a
(mTNF-a) activates both TNF-R1 and TNF-R2 on mur-
ine macrophages, while human TNF-a (hTNF-a) acti-
vates TNF-R1 only, thereby providing a means to
distinguish effects that are mediated through different
receptors [27]. mTNF-a and hTNF-a provided compar-
able protection from MTX-induced caspase-3 activation
(Figure 2, P > 0.05), indicating that protection is
mediated through TNF-R1, and does not require TNF-
R2 signaling.
NF-B is required for the survival effect of TNF-a in
macrophages
TNF-R1 ligation activates several pro-survival pathways
via its association with TRAF2 (TNFR-Associated Factor
2), RIP (Receptor-Interacting Protein) c-Src and Jak2.
These include the NF-B pathway, Phosphatidylinositol-
3-Kinase/Protein Kinase B (PI3K/AKT) and Mitogen-
Activated Protein Kinase pathways [28,29]. Constitutive
NF-B activity is critical to macrophage survival [26].
Therefore, we next examined the kinetics of NF-B acti-
vation in TNF-a-stimulated macrophages and investi-
gated whether NF-B activity was required for the
anti-apoptotic effect of TNF-a.
Proteosomal degradation of the NF-B inhibitory pro-
tein, IBa, is an early indicator of activation in the
canonical NF-B pathway [30]. TNF-a (10 ng/mL)
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IBa within 15 minutes (Figure 3A, P < 0.05). This cor-
responded to the appearance of DNA-binding NF-Bi n
the nucleus, with activity peaking at 30 minutes before
returning to baseline levels by one hour (Figure 3B).
Supershift analyses with specific antibodies to RelA,
NF-B1, c-Rel and Rel-B identified RelA (p65) and
NF-B1 (p50) as the main components of the NF-B
complex induced by TNF-a (Figure 3B). A light c-Rel
supershifted band was also detected (Figure 3B). IBa
Figure 1 TNF-a antagonises MTX-induced apoptosis in macrophages, independent of M-CSF action. A.E x p o s u r eo fp r i m a r yB M D Mt o
10 mM MTX for 24 hr in the presence of 30 ng/mL M-CSF resulted in loss of approximately 25% of cells. This could be entirely prevented by
introducing TNF-a three hours before MTX. Cell viability was assessed by the MTT reduction assay. Shown are mean ± SEM of normalised data
from three independent experiments. B and D, TNF-a suppresses caspase-3 activation (left axis) and annexin-V binding (right axis) in MTX-
exposed primary BMDM (B) and RAW264.7 cells (D). MTX was added three hours after TNF-a treatment, and caspase-3 activity or annexin-V
binding was measured after 24 hr for BMDM and 6 hr for RAW264.7 cells. Data are mean ± SEM of at least four independent experiments in each
case. C and E, MTX dose-dependently increases apoptosis in BMDM (C) and RAW264.7 cells (E). * = P < 0.05; ** = P < 0.01.
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is also NF-B-responsive, so early recovery of IBa levels
indicates functional NF-B signaling [30]. Lastly, TNF-a
stimulation of RAW264.7 cells transiently expressing a
NF-B-responsive reporter construct showed that NF-B
transcriptional activity was enhanced in a time-dependent
manner (Figure 3C). These results confirm that TNF-a is
a rapid activator of NF-B function in macrophages.
To investigate whether NF-B activity is essential for
TNF-a activity against MTX-induced apoptosis, the ses-
quiterpene lactone parthenolide (PAR) and BAY11-7085
(BAY) were used to specifically prevent NF-B signaling
[19,31]. PAR and BAY pre-treatment for 30 minutes
abolished both constitutive and TNF-a-stimulated
NF-B transcriptional activity (Figure 4A). They also
completely prevented TNF-a from rescuing RAW264.7
cells (Figure 4B,C) and primary macrophages (Figure
4D-F) from MTX-induced apoptosis and caspase-3 acti-
vation. These findings indicate that NF-B activation is
required for TNF-a protection against apoptosis
induced by MTX. Notably, TNF-a became pro-
apoptotic, rather than anti-apoptotic when NF-Bs i g -
naling was blocked, when estimated by either annexin-V
binding (P < 0.05) or caspase-3 activity (P < 0.05).
The involvement of PI3K/AKT, ERK, JNK and p38 MAP
kinases was also explored using their specific inhibitors,
but they were found to be dispensable for TNF-a-induced
survival of macrophages, as assessed by annexin-V staining
and caspase-3 activity (results not shown).
Autocrine TNF-a signaling is not required for basal
survival of M-CSF-maintained macrophages
Macrophages are also sources of TNF-a,r a i s i n gt h e
possibility that constitutive NF-B activity (and thus
survival) depended on autocrine TNF-a stimulation.
We, therefore, treated BMDM cultures with etanercept,
a chimeric protein comprising Fc domains of human
IgG1 and TNF-a-binding domains of the Type 2 TNF
receptor, which neutralises both murine and human
TNF-a [32]. An irrelevant human myeloma-derived
IgG1 served as a control. Etanercept, however, did not
increase caspase-3 activation, indicating that autocrine
TNF-a stimulation was not important for survival of
macrophages cultured with optimal concentrations of
M-CSF (results not shown).
RANKL, a weak activator of NF-B in macrophages, does
not protect from MTX-induced apoptosis
The observation that TNF-a protected macrophages from
MTX-induced apoptosis led us to question whether other
cytokines present in rheumatoid synovium or erosions
may also protect through NF-B induction. Receptor Acti-
vator of NF-B Ligand (RANKL) circulates at elevated
concentration in RA and is demonstrable in rheumatoid
synovium and erosions [33]. It is required for osteoclast
formation from monocyte/macrophage precursors. Unlike
TNF-a, however, RANKL did not suppress caspase-3 acti-
vation in MTX-exposed primary macrophage cultures at
concentrations up to 400 ng/mL (Figure 5A). A dose of
200 ng/mL of RANKL is sufficient to elicit classical
Table 1 Cell cycle analysis of BMDM treated with TNF-a
or its control, followed by MTX exposure for 24 hr or
M-CSF withdrawal for 48 hr*
Cell cycle distribution (% of cells)
sub G0 G0/G1 S G2/M
Control 3.5 ± 0.5 78.6 ± 2.9 6.0 ± 1.0 10.7 ± 2.7
MTX (10 μM) 7.5 ± 1.0
a 62.7 ± 2.2
a 16.0 ± 1.2
a 12.0 ± 1.2
TNF-a (10 ng/mL) 3.6 ± 0.4 77.0 ± 2.2 7.5 ± 1.7 10.7 ± 2.0
TNF-a + MTX 5.8 ± 0.8
b 65.7 ± 4.8 13.8 ± 3.2 13.1 ± 2.6
M-CSF (30 ng/mL) 1.5 ± 0.4 74.2 ± 2.6 8.4 ± 1.9 13.9 ± 2.2
- M-CSF 15.4 ± 4.1
a 74.7 ± 5.1 2.8 ± 0.7
a 5.5 ± 0.9
a
M-CSF + TNF-a 1.5 ± 0.2 71.8 ± 1.9 9.3 ± 1.3 15.3 ± 2.7
- M-CSF + TNF-a 4.4 ± 2.3
b 82.3 ± 3.7
b 1.9 ± 0.4 9.7 ± 2.7
*Results are mean ± SEM of at least three independent experiments in each
case.
aP < 0.05 compared to controls.
bP < 0.05 compared to MTX alone or no
M-CSF.
BMDM, bone marrow-derived macrophages; M-CSF, macrophage colony
stimulating factor; MTX, methotrexate; TNF-a, tumor necrosis factor-alpha.
Figure 2 Human (h) and murine (m) TNF-a confer comparable
protection against apoptosis in RAW264.7 cells exposed to 10
mM MTX. Caspase-3 activity was measured after six hours with MTX,
without TNF-a, or pre-treated with 10 ng/mL mTNF-a or hTNF-a for
three hours. Shown are mean ± SEM of three independent
experiments. * = P < 0.05.
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Page 6 of 13Figure 3 TNF-a activates NF-kB in RAW264.7 cells. A. TNF-a promotes degradation of IkBa and resynthesis over 60 minutes. IBa and b-actin
protein levels were assessed by Western blot analysis and quantified by densitometry (lower panel). Densitometry data show IBa levels that
were corrected by b-actin and represent normalised data from four independent experiments. * = P < 0.05. B. EMSA for NF-kB proteins in
nuclear extracts of RAW264.7 cells over six hours of TNF-a exposure. The arrow on the left indicates the position of the RelA/NF-kB1 heterodimer.
Competition for binding by an unlabeled specific oligonucleotide (lane 7) but not by an irrelevant sequence at 100-fold molar excess (lane 6)
confirmed specificity of DNA binding. Supershift analyses with specific antibodies to RelA, NF-kB1 (p50), c-Rel and RelB (lanes 9, 10, 11 and 12,
respectively, of the right panel) confirmed the identities of RelA and NF-kB1 in the complex with a lighter supershift c-Rel band. Arrows on the
right indicate the locations of supershifted bands. The figure is representative of two independent experiments. C. TNF-a (10 ng/ml) induces
NF-kB activity, as estimated by luciferase activity in RAW264.7 cells that had been transiently transfected with the pNF-kB-TA-Luc reporter. Results
are representative of three independent experiments.
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other experiments. Comparing effects on NF-Ba c t i -
vation, we found that RANKL (six hours) stimulated
an approximately three-fold increase in NF-B-lucifer-
ase reporter expression in transfected BMDM, well
short of the approximately 22-fold increase with TNF-
a (Figure 5B). Western blot analyses also indicated
weaker phosphorylation and degradation of IBa after
RANKL treatment, compared to TNF-a (Figure 5C).
Therefore, RANKL does not protect differentiated pri-
mary macrophages from MTX, possibly due to insuffi-
cient activation of NF-B.
Figure 4 TNF-a must activate NF-kB signaling to protect macrophages from MTX-induced apoptosis. A.P A Ra n dB A Y( 1 0μM) prevent
TNF-a-induced NF-kB activity in RAW264.7 cells, as measured by activity of the pNF-kB-TA-Luc reporter. Inhibitors were introduced 30 minutes
before TNF-a and luciferase activity was measured nine hours later. Results are mean ± SEM of at least four independent experiments. B-F. PAR
and BAY (10 mM or 7.5 mM) prevent TNF-a from rescuing MTX-treated RAW264.7 cells (B and C) and BMDM (D-F) from apoptosis. Cells were
exposed to PAR (B, D, and E) or BAY (C and F) for 30 minutes before TNF-a stimulation for three hours, after which MTX was introduced.
Annexin-V binding and/or caspase-3 activity was measured 6 hours later in RAW264.7 cells and 24 hours later in BMDM. Results are mean ± SEM
of at least three independent experiments in each case. Normalised data are shown for BAY experiments. * = P < 0.05; ** = P < 0.01.
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suppression
The observation that NF-B induction countered the
apoptotic action of MTX led us to test whether MTX
itself acted through inhibiting NF-B. This has been
previously observed in Jurkat T-cells and in the poorly
differentiated myelo-monocytic U937 cell line [35].
However, MTX, at concentrations sufficient to induce
apoptosis, failed to suppress either basal or TNF-a-
induced NF-Ba c t i v i t yi nR A W 264.7 cells transiently
transfected with a specific NF-B reporter construct
(pNF-B-TA-Luc) (Figure 6A). In BMDM, it also failed
to prevent the TNF-a-stimulated phosphorylation of
IBa, an essential step in IBa degradation and RelA/
NF-B1 complex release (Figure 6B). MTX, therefore,
does not exert its apoptotic actions through NF-B
suppression.
Anti-inflammatory actions of MTX on macrophages
have been attributed to enhanced extracellular adeno-
sine generation. However, neither adenosine itself (Fig-
ure 6C), or the pan-adenosine receptor agonist NECA
(Figure 6D), affected caspase-3 activity. Thus, adenosine
accumulation alone is not a sufficient explanation for
MTX-induced macrophage apoptosis.
Discussion
TNF-a protects macrophages from apoptosis induced by
MTX. This offers an explanation for the clinical obser-
vation that anti-TNF-a treatments cause apoptosis of
monocyte/macrophage lineage cells in peripheral blood
and synovium of patients with RA [4], in a study where
most participants were also taking MTX. The survival
signal from TNF-a is transduced through TNF-R1 and
the canonical NF-B pathway. M-CSF, which directs
Figure 5 RANKL, a weak NF-B activator, does not protect primary BMDM from MTX-induced apoptosis. A. RANKL (100 to 400 ng/mL)
was introduced to BMDM 6 hours before MTX (10 mM) treatment. Caspase-3 activity was measured 24 hours later. Results are mean ± SEM
from at least six independent experiments. B. and C. Compared to RANKL (200 ng/mL), TNF-a (10 ng/mL) treatment causes greater activation of
NF-kB in BMDM. Cells transiently expressing the pNF-kB-TA-Luc reporter were stimulated with RANKL or TNF-a for six hours (B). Shown are mean
± SEM of normalised data from three independent experiments. C. Cells were M-CSF-starved overnight before stimulation with RANKL or TNF-a
for 10 minutes and 30 minutes. Whole-cell lysates were subjected to western blot analysis for phosphorylated IkBa, total IkBa and b-actin. Results
are representative of three independent experiments. * = P < 0.05; ** = P < 0.01.
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Page 9 of 13macrophage differentiation, growth and survival, but
does not activate NF-B signaling, cannot substitute for
TNF-a.T h i si sn o t a b l e ,b e c a u s eM - C S Fi sp r e s e n ti n
peripheral blood and synovial fluid in RA [22], and
might have been expected to render anti-apoptotic
effects of TNF-a redundant. M-CSF signals for growth
and survival primarily through the PI3K/AKT pathway.
TNF-a can activate both pro-apoptotic and anti-apoptotic
pathways, with outcomes that differ between cell types and
conditions. The importance of NF-B signaling in survival
is highlighted by the outcomes of PAR and BAY exposure,
which converted TNF-a f r o mad o m i n a n t l yp r o - s u r v i v a l
signal to an apoptotic signal. NF-B-regulated proteins that
have been linked to inhibition of apoptotic signaling include
T R A F - 1 ,T R A F - 2 ,c I A P - 1 ,c I A P - 2 ,X I A P ,F L I P ,A 2 0 ,
GADD45b, the antioxidant Mn-SOD, and anti-apoptotic
members of the Bcl-2 family, such as A1 and Bcl-xL [36].
The canonical NF-B pathway is activated in macro-
phages of rheumatoid synovium [12], consistent with a
role in maintaining cell survival in untreated patients
[10,11]. Other products of the inflamed synovium,
including IL-1, RANKL, GM-CSF, VEGF, PDGF and
leukotrienes [37] can promote NF-B signaling in
responsive cells and may contribute, with TNF-a,t o
NF-B activation in macrophages of rheumatoid syno-
vium. However, the experiments with RANKL indicated
that not all NF-B activators protect from apoptosis.
RANKL failed to protect primary murine macrophages
from MTX-induced apoptosis, even at concentrations
that promote osteoclastogenesis in our hands [34] and
Figure 6 MTX does not inhibit TNF-a-induced NF-kB activity. A. Reporter-expressing RAW264.7 cells were exposed to MTX for one hour or
two hour before TNF-a stimulation for a further three hour. Shown are mean ± SEM of four independent experiments. B. BMDM were pre-
treated with MTX for two hour before TNF-a stimulation for 10 minutes. Whole-cell lysates were probed with antibodies for phosphorylated IkBa,
total IkBa and b-actin. C. Adenosine and D. NECA do not increase basal macrophage apoptosis. BMDM were exposed to increasing
concentrations of adenosine or NECA for 24 hour before caspase-3 measurements. Shown are mean ± SEM of results from three independent
experiments in each case. ** = P < 0.01.
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Page 10 of 13which exceed the concentrations reported in rheumatoid
synovial fluid [38]. The difference may arise because
RANKL activates NF-B less intensely, or because of dif-
ferences in other pathways recruited by TNF-R1 and
RANK. Finding that RANKL is not a survival factor for
macrophages mirrors findings with osteoclast precursors,
where RANKL promotes activation and differentiation,
but not survival [39]. The mature osteoclast, however, is
protected from apoptosis by RANKL with mixed reports
of NF-B involvement [40]. The finding that RANKL-
induced NF-B activation is insufficient to protect pri-
mary macrophages from apoptosis is also in accord with
the conclusion from clinical studies, that RANKL is not
an important driver of synovial inflammation in RA, even
though it is critical for erosion formation [41].
MTX has been reported to suppress NF-B activity in
a different cell context [35]. However, NF-Bs u p p r e s -
sion could not be demonstrated in MTX-exposed
macrophages, so cannot be the mechanism of MTX-
induced macrophage apoptosis. MTX anti-inflammatory
response has also been linked with the extracellular
accumulation of adenosine. Adenosine is reported to
promote apoptosis of colon cancer cells in vitro [42],
but we could find no evidence that adenosine alone
causes apoptosis in macrophages. The experiments
could not disprove a permissive role for adenosine. The
experiments do, however, prove that MTX and TNF-a
do not just act conversely on NF-B signaling. MTX has
many potentially apoptotic actions [3,13,15] and NF-B
has many anti-apoptotic actions [36]. It, therefore,
seems more likely that the fate of TNF-a and MTX-
exposed macrophages is decided by the late effectors of
apoptosis signaling, particularly at mitochondrial steps,
that integrate and balance multiple converging inputs
[43]. This requires better definition.
Macrophage NF-B signaling is an attractive therapeu-
tic target in RA because of roles in inflammation, differ-
entiation and survival. However, NF-Bp a t h w a y sa r e
employed in diverse tissues, with broad biological conse-
quences. Anti-TNF-a treatments suppress NF-Ba c t i v -
ity in circumstances where it is promoted by TNF-a,
such as in the synovial macrophage. Currently available
NF-B-suppressing small molecules, however, lack such
cellular specificity. Glucocorticoids suppress macrophage
NF-B activity, but with poor specificity [21]. The pro-
teosomal inhibitor, bortezomib, suppresses NF-Bs i g -
naling by preventing IBa degradation and is reported
to reduce synovial macrophage inflammatory activity in
experimental murine collagen arthritis [44] but, again, is
not specifically targeted to the macrophage. Thalidomide
likewise suppresses clinical activity of systemic onset
juvenile RA [45], and leads to monocyte apoptosis in
vitro through actions on AKT-1 [46] and NF-B signal-
ing [47], but with the attendant threat of teratogenesis
and other serious off-target effects. Developing macro-
phage-specific NF-B suppressants may also have to
contend with internal redundancy, with RelA and cRel
able to serve similar functions for apoptosis suppression
in haematopoietic cells [48].
Conclusions
We were able to confirm that the potent NF-B activator,
TNF-a, counters MTX-induced apoptosis in primary
murine macrophages. A less potent activator, RANKL,
could not. Neither could the primary macrophage differ-
entiation and survival factor, M-CSF, which we found did
not activate NF-B signaling. However, MTX did not
suppress either constitutive or induced NF-B signaling,
ruling out a direct apoptotic action through NF-Bi n h i -
bition. These findings provide an additional explanation
for the clinical complementarity between MTX and anti-
TNF-a treatments for rheumatoid arthritis.
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